New cancer drug combo shows early promise in Tough-to-Treat tumors
NCT ID NCT02964013
Summary
This first-in-human study tested the safety and early effectiveness of a new drug called vibostolimab. It was given alone and in combination with an existing immunotherapy (pembrolizumab) to 474 adults with advanced solid tumors that had stopped responding to other treatments. The main goal was to find a safe dose for future studies and see if the drug combination could help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.